Your browser doesn't support javascript.
loading
Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States.
Perofsky, Amanda C; Huddleston, John; Hansen, Chelsea L; Barnes, John R; Rowe, Thomas; Xu, Xiyan; Kondor, Rebecca; Wentworth, David E; Lewis, Nicola; Whittaker, Lynne; Ermetal, Burcu; Harvey, Ruth; Galiano, Monica; Daniels, Rodney Stuart; McCauley, John W; Fujisaki, Seiichiro; Nakamura, Kazuya; Kishida, Noriko; Watanabe, Shinji; Hasegawa, Hideki; Sullivan, Sheena G; Barr, Ian G; Subbarao, Kanta; Krammer, Florian; Bedford, Trevor; Viboud, Cécile.
Afiliación
  • Perofsky AC; Fogarty International Center, National Institutes of Health, Bethesda, United States.
  • Huddleston J; Brotman Baty Institute for Precision Medicine, University of Washington, Seattle, United States.
  • Hansen CL; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, United States.
  • Barnes JR; Fogarty International Center, National Institutes of Health, Bethesda, United States.
  • Rowe T; Brotman Baty Institute for Precision Medicine, University of Washington, Seattle, United States.
  • Xu X; Virology Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention (CDC), Atlanta, United States.
  • Kondor R; Virology Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention (CDC), Atlanta, United States.
  • Wentworth DE; Virology Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention (CDC), Atlanta, United States.
  • Lewis N; Virology Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention (CDC), Atlanta, United States.
  • Whittaker L; Virology Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention (CDC), Atlanta, United States.
  • Ermetal B; WHO Collaborating Centre for Reference and Research on Influenza, Crick Worldwide Influenza Centre, The Francis Crick Institute, London, United Kingdom.
  • Harvey R; WHO Collaborating Centre for Reference and Research on Influenza, Crick Worldwide Influenza Centre, The Francis Crick Institute, London, United Kingdom.
  • Galiano M; WHO Collaborating Centre for Reference and Research on Influenza, Crick Worldwide Influenza Centre, The Francis Crick Institute, London, United Kingdom.
  • Daniels RS; WHO Collaborating Centre for Reference and Research on Influenza, Crick Worldwide Influenza Centre, The Francis Crick Institute, London, United Kingdom.
  • McCauley JW; WHO Collaborating Centre for Reference and Research on Influenza, Crick Worldwide Influenza Centre, The Francis Crick Institute, London, United Kingdom.
  • Fujisaki S; WHO Collaborating Centre for Reference and Research on Influenza, Crick Worldwide Influenza Centre, The Francis Crick Institute, London, United Kingdom.
  • Nakamura K; WHO Collaborating Centre for Reference and Research on Influenza, Crick Worldwide Influenza Centre, The Francis Crick Institute, London, United Kingdom.
  • Kishida N; Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Watanabe S; Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Hasegawa H; Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Sullivan SG; Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Barr IG; Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • Subbarao K; WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Krammer F; WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Bedford T; WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Viboud C; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, United States.
Elife ; 132024 Sep 25.
Article en En | MEDLINE | ID: mdl-39319780
ABSTRACT
Influenza viruses continually evolve new antigenic variants, through mutations in epitopes of their major surface proteins, hemagglutinin (HA) and neuraminidase (NA). Antigenic drift potentiates the reinfection of previously infected individuals, but the contribution of this process to variability in annual epidemics is not well understood. Here, we link influenza A(H3N2) virus evolution to regional epidemic dynamics in the United States during 1997-2019. We integrate phenotypic measures of HA antigenic drift and sequence-based measures of HA and NA fitness to infer antigenic and genetic distances between viruses circulating in successive seasons. We estimate the magnitude, severity, timing, transmission rate, age-specific patterns, and subtype dominance of each regional outbreak and find that genetic distance based on broad sets of epitope sites is the strongest evolutionary predictor of A(H3N2) virus epidemiology. Increased HA and NA epitope distance between seasons correlates with larger, more intense epidemics, higher transmission, greater A(H3N2) subtype dominance, and a greater proportion of cases in adults relative to children, consistent with increased population susceptibility. Based on random forest models, A(H1N1) incidence impacts A(H3N2) epidemics to a greater extent than viral evolution, suggesting that subtype interference is a major driver of influenza A virus infection ynamics, presumably via heterosubtypic cross-immunity.
Seasonal influenza (flu) viruses cause outbreaks every winter. People infected with influenza typically develop mild respiratory symptoms. But flu infections can cause serious illness in young children, older adults and people with chronic medical conditions. Infected or vaccinated individuals develop some immunity, but the viruses evolve quickly to evade these defenses in a process called antigenic drift. As the viruses change, they can re-infect previously immune people. Scientists update the flu vaccine yearly to keep up with this antigenic drift. The immune system fights flu infections by recognizing two proteins, known as antigens, on the virus's surface, called hemagglutinin (HA) and neuraminidase (NA). However, mutations in the genes encoding these proteins can make them unrecognizable, letting the virus slip past the immune system. Scientists would like to know how these changes affect the size, severity and timing of annual influenza outbreaks. Perofsky et al. show that tracking genetic changes in HA and NA may help improve flu season predictions. The experiments compared the severity of 22 flu seasons caused by the A(H3N2) subtype in the United States with how much HA and NA had evolved since the previous year. The A(H3N2) subtype experiences the fastest rates of antigenic drift and causes more cases and deaths than other seasonal flu viruses. Genetic changes in HA and NA were a better predictor of A(H3N2) outbreak severity than the blood tests for protective antibodies that epidemiologists traditionally use to track flu evolution. However, the prevalence of another subtype of influenza A circulating in the population, called A(H1N1), was an even better predictor of how severe A(H3N2) outbreaks would be. Perofsky et al. are the first to show that genetic changes in NA contribute to the severity of flu seasons. Previous studies suggested a link between genetic changes in HA and flu season severity, and flu vaccines include the HA protein to help the body recognize new influenza strains. The results suggest that adding the NA protein to flu vaccines may improve their effectiveness. In the future, flu forecasters may want to analyze genetic changes in both NA and HA to make their outbreak predictions. Tracking how much of the A(H1N1) subtype is circulating may also be useful for predicting the severity of A(H3N2) outbreaks.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glicoproteínas Hemaglutininas del Virus de la Influenza / Gripe Humana / Subtipo H3N2 del Virus de la Influenza A / Epidemias / Deriva y Cambio Antigénico Límite: Adolescent / Adult / Child / Child, preschool / Humans / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Elife Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glicoproteínas Hemaglutininas del Virus de la Influenza / Gripe Humana / Subtipo H3N2 del Virus de la Influenza A / Epidemias / Deriva y Cambio Antigénico Límite: Adolescent / Adult / Child / Child, preschool / Humans / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Elife Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido